ENTA
Enanta·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
EPS Beats Expectation
Consecutive Revenue Decline
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ENTA
Enanta Pharmaceuticals, Inc.
A company that developing small molecule drugs for viral infections and liver diseases
4 Kingsbury Avenue , Watertown, Massachusetts 02472
--
Enanta Pharmaceuticals, Inc., was incorporated in 1995 under the laws of the State of Delaware. The company is a biotechnology company that utilizes powerful, chemically driven methods and drug discovery capabilities to discover and develop small molecule drugs for virological and immunological indications.
Company Financials
EPS
ENTA has released its 2025 Q4 earnings. EPS was reported at -0.87, versus the expected -1.01, beating expectations. The chart below visualizes how ENTA has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ENTA has released its 2025 Q4 earnings report, with revenue of 15.13M, reflecting a YoY change of 3.55%, and net profit of -18.70M, showing a YoY change of 35.12%. The Sankey diagram below clearly presents ENTA's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
